University of Maryland Medical Center

Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, MD

Sorting 2 by

Accepting patients

Cirtuvivint

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Dual Specificity TK Inhibitor (DYRK)
  • CLK Inhibitor
  • Phase 1

Accepting patients

MGD024

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Learn more
  • Bispecific Antibody
  • Phase 1